182 filings
Page 4 of 10
8-K
skndqje1n kxprmb2u5b
9 Feb 21
Termination of a Material Definitive Agreement
4:59pm
8-K
h7il f0o8drmno1ow19
27 Jan 21
KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
9:17am
8-K
sj50i8s
26 Jan 21
Entry into a Material Definitive Agreement
9:16am
8-K
rutajk
13 Jan 21
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
12:00am
8-K
p28yh9j
5 Jan 21
Sven Guenther, Ph.D., our executive vice president, research and development; and Summary Compensation Table
9:10am
8-K
vytr0
28 Dec 20
Entry into a Material Definitive Agreement
6:15am
8-K
9a50n9e d8
28 Dec 20
KemPharm Announces 1-for-16 Reverse Stock Split
12:00am
8-K
q32f7wgi7rflfk6d
21 Dec 20
Entry into a Material Definitive Agreement
6:06am
8-K/A
966ohdus
23 Nov 20
KemPharm Provides Update on Development Pipeline
9:23pm
8-K
ac19qhmp6oxxk
23 Nov 20
KemPharm Provides Update on Development Pipeline
4:54pm
8-K
cjcxtzco av39
19 Nov 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K/A
un160hq ijn1dis
30 Oct 20
KemPharm Reports Third Quarter 2020 Financial Results
12:00am
8-K
l66alavrzgdg
29 Oct 20
KemPharm Reports Third Quarter 2020 Financial Results
4:27pm
8-K
b9qv2ngibtaj0wlt9k8r
26 Oct 20
KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call
8:48am
8-K
e8alj3p vy
25 Sep 20
KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
5:02pm
8-K
x3gq5a6h1cnt1
12 Aug 20
KemPharm Reports Second Quarter 2020 Financial Results
4:32pm
8-K
ch0 ec6w7umra
17 Jul 20
Amendments to Articles of Incorporation or Bylaws
4:21pm
8-K
z2xy6bbav05f exqwv
24 Jun 20
Other Events
4:13pm
8-K
8y66gyzx222n 8c
19 Jun 20
Submission of Matters to a Vote of Security Holders
4:09pm
8-K/A
2g06s8xz si7
19 Jun 20
KemPharm Issues Letter to Shareholders
12:00am